Gene editing technologies

Gene-editing, and targeting capabilities of components of gene-editing systems, can be harnessed to provide wide-ranging, practical applications, yet freedom to operate issues often pose ongoing challenges for pioneers and start-ups in this fast-moving, powerful field.  

Whilst there is immense focus on CRISPR gene-editing, older techniques continue to have applications, with the early systems providing impetus for further developments in genetic modification in the CRISPR field and beyond.  

HGF has one of the most experienced, commercially- minded teams in Europe focussed on gene-editing, with significant experience of involvement in European oppositions affecting the foundational CRISPR IP,  as well as advising on and patenting earlier gene-editing systems, such as TALENs.  

The core team of specialists that make-up the HGF CRISPR team are backed by a larger group of over 75 patent attorneys and solicitors, with backgrounds in life sciences, pharmaceuticals, chemistry and plant sciences.  

Specialising in gene-editing in the context of new human and animal therapies, viral diagnostics, developments in animal farming and microbiome, as well as plant protection and breeding, the HGF CRISPR team includes specialists from the firm’s AgBio team. This enables HGF to develop multidisciplinary IP strategies across this important and complex field.  

HGF works with pioneers of CRISPR technology, as well as for clients advancing the field of gene modification and applications of CRISPR, to those that endeavour to resolve important problems, such as antibiotic resistance and infection diagnostics. This wealth of expertise sees HGF attorneys conducting talks at international events and providing articles on IP developments in the fast-evolving CRISPR field, along with the broader genetic engineering sector.

Latest updates

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 23rd March 2022

HGF webinar: Getting your first filing right

HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …

Event details

The Microbiome Times: ELIGO v SNIPR: a reflection on IP strategies in a competitive environment

HGF Partner and Patent Attorney Craig Thomson and Patent Director Dr Jennifer Bailey write an article for The Microbiome Times on ELIGO v SNIPR: a reflection on IP strategies in …

Read article

Getting your first filing right

One of the most often asked questions of patent attorneys is “when should we file?” Both timing and content of a first filing should be important strategic decisions. This is …

Read article

Start-ups & IP, a case study: SleepCogni

Using SleepCogni as a case study, we look at some key ways that IP can help start-ups to develop their technology and secure investment. SleepCogni is a SleepTech start-up who …

Read article
Event - 26th October 2021

9th Microbiome R&D and Business Collaboration Forum: Europe

9th Microbiome R&D and Business Collaboration Forum: Europe will be held on 26th-27th October 2021 in Rotterdam, The Netherlands. The event is dedicated to exploring microbiome research and strategies for …

Event details
Event - 21st October 2021

Medical Technology Ireland Conference 2021

Medical Technology Ireland Conference will be held on 20-21 October 2021 at the Galway Racecourse. Medical Technology Ireland Conference features presentations by leading international medical device experts with thought-provoking guest …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our gene editing technologies specialists.